Lynparza 100 mg/1

Lynparza 100 mg is a medication used in cancer treatment. It contains olaparib, a PARP inhibitor, and is available in film-coated tablet form. This drug is manufactured by AstraZeneca Pharmaceuticals LP.

Lynparza 100 mg is primarily used in the treatment of certain types of cancer. It works by targeting specific enzymes involved in DNA repair, which can help slow the growth of cancer cells. This medication is often prescribed for patients with specific genetic mutations that affect DNA repair mechanisms. Lynparza 100 mg is used for the maintenance treatment of advanced ovarian cancer and other types of cancer that have responded to previous treatments.

Common effects of Lynparza 100 mg may include fatigue, nausea, vomiting, and anemia. Some patients may also experience diarrhea, constipation, or changes in taste. It is important to discuss any persistent or severe side effects with a healthcare provider. Lynparza 100 mg may also cause low blood cell counts, which can increase the risk of infections or bleeding.

Lynparza 100 mg should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions. Pregnant women or those planning to become pregnant should discuss the risks and benefits with their healthcare provider before starting Lynparza 100 mg.

Lynparza 100 mg may interact with certain medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol and other substances that affect liver function may also interact with Lynparza 100 mg. Always consult a healthcare professional before starting or stopping any medication while taking Lynparza 100 mg.